Fingerprint
Dive into the research topics of '90Y-ibritumomab tiuxetan radiotherapy as first-line therapy for early stage low-grade B-cell lymphomas, including bulky disease'. Together they form a unique fingerprint.- Sort by
- Weight
- Alphabetically
90Y-ibritumomab tiuxetan radiotherapy as first-line therapy for early stage low-grade B-cell lymphomas, including bulky disease
Felipe Samaniego*, Zuzana Berkova, Jorge E. Romaguera, Nathan Fowler, Michelle A. Fanale, Barbara Pro, Jatin J. Shah, Peter Mclaughlin, Lalit Sehgal, Vijairam Selvaraj, Frank K. Braun, Rohit Mathur, Lei Feng, Sattva S. Neelapu, Larry W. Kwak
*Corresponding author for this work
Research output: Contribution to journal › Article › peer-review
24
Scopus
citations